Oryzon Genomics SA represents core values of innovation, integrity, and collaboration. This biopharmaceutical company is committed to advancing precision medicine through cutting-edge research and development. With a focus on epigenetics, Oryzon Genomics SA aims to discover and develop novel therapies for serious diseases such as cancer and neurodegenerative disorders. The company's corporate philosophy revolves around ethically transforming scientific knowledge into tangible solutions for patients worldwide. By fostering partnerships and leveraging its expertise, Oryzon Genomics SA strives to bring about meaningful advancements in the field of personalized medicine.

Oryzon Genomics SA is primarily present in Spain and the United States.

Oryzon Genomics SA has achieved several significant milestones. The company successfully completed various clinical trials, including Phase II and Phase IIB studies, for its lead investigational drug, vafidemstat. They have also garnered positive results in these trials, demonstrating the drug's potential for the treatment of various neurological and psychiatric disorders. Oryzon Genomics SA has secured several partnerships and collaborations with renowned institutions and pharmaceutical companies to further advance their research and development efforts. They have also received important regulatory designations, such as Orphan Drug Designation from the U.S. FDA, further validating the potential of their innovative therapies.

Oryzon Genomics SA is a biopharmaceutical company specializing in epigenetics and precision medicine. Founded in 2000, the Spanish-based company emerged from a joint initiative of scientists and researchers from the University of Barcelona and the Spanish National Research Council. Oryzon Genomics focuses on the development of innovative therapies for serious diseases, such as cancer and neurological disorders, by modulating gene expression through epigenetic mechanisms. They employ cutting-edge technologies and have a robust pipeline of investigational drugs under development. Oryzon Genomics aims to bring novel and effective treatment options to patients and contribute to advancing the field of precision medicine.

Some of the main competitors of Oryzon Genomics SA in the market include other companies in the field of biotechnology and pharmaceuticals. These can include companies like Roche Holding AG, Novartis AG, and Amgen Inc.

Oryzon Genomics SA is primarily active in the biotechnology industry.

The business model of Oryzon Genomics SA revolves around the development and commercialization of innovative epigenetic therapies. As a biopharmaceutical company, Oryzon focuses on the research and discovery of new drugs to treat diseases associated with altered gene expression. By targeting specific epigenetic marks, they aim to regulate gene activity and restore normal cellular function. Oryzon Genomics SA collaborates with academic institutions and pharmaceutical companies to advance their therapies through preclinical and clinical development stages. With a focus on epigenetics, Oryzon strives to provide novel therapeutic solutions for diseases such as cancer, neurological disorders, and autoimmune conditions.

De Oryzon Genomics K/W is -31,28.

De Oryzon Genomics KUV is 59,18.

De AlleAktien Kwaliteitsscore voor Oryzon Genomics is 2/10.

De verwachte Oryzon Genomics omzet is 1,87 mln. EUR.

De verwachte Oryzon Genomics winst is -3,53 mln. EUR.

Oryzon Genomics SA is a biotechnology company specializing in the development of epigenetic-based therapies for neurodegenerative diseases and cancer. The company is headquartered in Spain and has been listed on the Madrid Stock Market since 2015. Oryzon Genomics SA's business model includes several divisions, each with a specific focus to achieve Oryzon's goal of providing innovative therapies for severe and chronic diseases. The main focus is on identifying enzymes involved in epigenetic changes that contribute to the onset of certain diseases. These enzymes are intended to serve as targets for the development of new drugs. The first division of Oryzon Genomics SA is the research and development of drugs. The company has various programs in the field of epigenetics focused on the development of therapeutics for severe diseases. This includes programs for Alzheimer's disease, multiple sclerosis, autism, depression, and various types of cancer. The company focuses on the discovery of new drug classes and works closely with academic institutions and pharmaceutical companies. Another important division of Oryzon is the Mechanism-of-Action (MOA) service. This service helps other pharmaceutical companies understand the mode of action of new drugs. Oryzon offers its service for the analysis of potential drug effectiveness and assists in identifying new therapeutic target structures. This is intended to enable other pharmaceutical companies to develop new drugs more quickly. The company also has a Clinical Development Unit that focuses on the clinical development of new drugs. In this division, data from animal studies and Phase I areas are used to test the efficacy and safety of compounds in clinical trials. The clinical development of drugs is a time-consuming and costly process, but it is also a crucial phase for the approval of a new drug. Another important area of Oryzon Genomics is its service business. Here, the company offers its expertise and experience in epigenetics to assist other pharmaceutical companies and academic institutions in the development of new drugs and diagnostics. The services offered include drug discovery services, analytical and preclinical services, molecular biology and epigenetic services, and assay development services. Finally, the company also offers products such as epigenetic kits and reagents for research. These products are intended to help scientists better understand the mechanisms of epigenetics and develop new therapeutic approaches. In summary, Oryzon Genomics SA's business model is focused on developing innovative therapies for severe and chronic diseases. The company identifies enzymes involved in epigenetic changes and uses them as targets for new drugs. The company has several divisions, including research and development, the MOA service, the Clinical Development Unit, and the service business. Oryzon Genomics SA also offers products such as epigenetic kits and reagents for research and strives to advance the development of new therapeutic approaches in epigenetics.

Oryzon Genomics keert een dividend van 0 EUR uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Oryzon Genomics of het bedrijf keert geen dividend uit.

De ISIN van Oryzon Genomics is ES0167733015.

Het WKN van Oryzon Genomics is A2ACV2.

De ticker van Oryzon Genomics is ORY.MC.

Binnen de laatste 12 maanden betaalde Oryzon Genomics een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Oryzon Genomics naar verwachting een dividend van 0 EUR betalen.

De dividendrendement van Oryzon Genomics is momenteel .

Oryzon Genomics betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Oryzon Genomics betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 EUR verwacht. Dit komt overeen met een dividendrendement van 0 %.

Oryzon Genomics wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Oryzon Genomics van 7-7-2024 ter hoogte van 0 EUR te ontvangen, moest je het aandeel voor de ex-datum op 7-7-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 7-7-2024.

In het jaar 2023 heeft Oryzon Genomics 0 EUR aan dividenden uitgekeerd.

De dividenden van Oryzon Genomics worden in EUR uitgekeerd.